Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma
M Rosellini, A Marchetti, V Mollica, A Rizzo… - Nature Reviews …, 2023 - nature.com
The therapeutic algorithm of renal cell carcinoma has been revolutionized by the approval of
immunotherapy agents by regulatory agencies. However, objective and durable responses …
immunotherapy agents by regulatory agencies. However, objective and durable responses …
Antigen presentation in cancer—mechanisms and clinical implications for immunotherapy
Over the past decade, the emergence of effective immunotherapies has revolutionized the
clinical management of many types of cancers. However, long-term durable tumour control …
clinical management of many types of cancers. However, long-term durable tumour control …
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness
Clear cell renal cell carcinomas (ccRCCs) represent∼ 75% of RCC cases and account for
most RCC-associated deaths. Inter-and intratumoral heterogeneity (ITH) results in varying …
most RCC-associated deaths. Inter-and intratumoral heterogeneity (ITH) results in varying …
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …
[HTML][HTML] Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer
Tumor behavior is intricately dependent on the oncogenic properties of cancer cells and
their multi-cellular interactions. To understand these dependencies within the wider …
their multi-cellular interactions. To understand these dependencies within the wider …
Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker …
YA Vano, R Elaidi, M Bennamoun, C Chevreau… - The Lancet …, 2022 - thelancet.com
Background We previously reported a 35-gene expression classifier identifying four clear-
cell renal cell carcinoma groups (ccrcc1 to ccrcc4) with different tumour microenvironments …
cell renal cell carcinoma groups (ccrcc1 to ccrcc4) with different tumour microenvironments …
Final overall survival and molecular analysis in IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously …
Importance Interim analyses of the IMmotion151 trial (A Study of Atezolizumab in
Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced …
Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced …
Artificial intelligence and radiomics in evaluation of kidney lesions: a comprehensive literature review
M Ferro, F Crocetto, B Barone… - Therapeutic …, 2023 - journals.sagepub.com
Radiomics and artificial intelligence (AI) may increase the differentiation of benign from
malignant kidney lesions, differentiation of angiomyolipoma (AML) from renal cell carcinoma …
malignant kidney lesions, differentiation of angiomyolipoma (AML) from renal cell carcinoma …
Clinical review on the management of metastatic renal cell carcinoma
J Tran, MC Ornstein - JCO Oncology Practice, 2022 - ascopubs.org
Renal cell carcinomas vary considerably in their tumor biology and disease course, which is
reflected in the range of treatment paradigms in localized and metastatic renal cell …
reflected in the range of treatment paradigms in localized and metastatic renal cell …
Artificial intelligence-driven biomedical genomics
As genomic research becomes more complex and data-rich, artificial intelligence (AI) has
emerged as a crucial tool for processing and analyzing high-dimensional genomic data …
emerged as a crucial tool for processing and analyzing high-dimensional genomic data …